Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on the Brain Distribution of a Novel BRAF Inhibitor: Vemurafenib (PLX4032)

Por Mittapalli, Rajendar K., Vaidhyanathan, Shruthi, Sane, Ramola, Elmquist, William F.
Publicado em 2012

Mechanisms Limiting Distribution of the Threonine-Protein Kinase B-RaF(V600E) Inhibitor Dabrafenib to the Brain: Implications for the Treatment of Melanoma Brain Metastases

Por Mittapalli, Rajendar K., Vaidhyanathan, Shruthi, Dudek, Arkadiusz Z., Elmquist, William F.
Publicado em 2013

Factors Influencing the CNS Distribution of a Novel MEK-1/2 Inhibitor: Implications for Combination Therapy for Melanoma Brain Metastases

Por Vaidhyanathan, Shruthi, Mittapalli, Rajendar K., Sarkaria, Jann N., Elmquist, William F.
Publicado em 2014

Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Res...

Por Vaidhyanathan, Shruthi, Wilken-Resman, Brynna, Ma, Daniel J., Parrish, Karen E., Mittapalli, Rajendar K., Carlson, Brett L., Sarkaria, Jann N., Elmquist, William F.
Publicado no J Pharmacol Exp Ther (2016)